Morgan Stanley Lowers Price Target on MetLife to $89 From $93, Keeps Overweight Rating

Morgan Stanley has adjusted its price target for MetLife (MET) to $89, down from the previous $93, while maintaining an “Overweight” rating on the stock. This update reflects a revised valuation perspective from the firm. The article also mentions recent MetLife developments including executive appointments and changes in S&P 100 listing.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin